Onco-Summaries: Daily Oncology Updates at a Glance

06/05/2026

---

• FDA grants Fast Track designation to Diakonos Oncology’s DOC1021 immunotherapy for advanced melanoma, advancing a novel dendritic cell therapy into Phase 1/2 trials

  
  

• Partner Therapeutics secures FDA Priority Voucher for BIZENGRI in NRG1+ cholangiocarcinoma, advancing rapid review of Phase 2 eNRGy data

  
  

• FDA accepts sNDA for IBTROZI® with >4‑year median response in ROS1+ NSCLC, reinforcing long‑term efficacy and global standard‑of‑care potential

---

FDA grants Fast Track designation to Diakonos Oncology’s DOC1021 immunotherapy for advanced melanoma, advancing a novel dendritic cell therapy into Phase 1/2 trials (Ref)

The FDA has granted Fast Track designation to Diakonos Oncology’s investigational therapy DOC1021 (dubodencel) for unresectable or metastatic cutaneous melanoma

Diakonos is advancing DOC1021 through ongoing and upcoming studies, including a Phase 1/2 trial in refractory melanoma, now recruiting

• DOC1021 is a first-in-class, patient-derived double-loaded dendritic cell therapy that combines tumor lysate and amplified tumor-derived mRNA

Return to Top

Partner Therapeutics secures FDA Priority Voucher for BIZENGRI in NRG1+ cholangiocarcinoma, advancing rapid review of Phase 2 eNRGy data (Ref)

Partner Therapeutics received a Commissioner’s National Priority Voucher (CNPV) for BIZENGRI® (zenocutuzumab-zbco) in NRG1 fusion–positive cholangiocarcinoma, recognizing the urgent unmet need in this ultra-rare cancer

A supplemental Biologics License Application (sBLA) was submitted based on Phase 2 eNRGy trial data. The drug already holds Breakthrough Therapy and Orphan Drug Designations

In the eNRGy trial, zenocutuzumab showed objective responses in over one-third of patients, with median progression-free survival >9 months, and a favorable tolerability profile

Return to Top

FDA accepts sNDA for IBTROZI® with >4‑year median response in ROS1+ NSCLC, reinforcing long‑term efficacy and global standard‑of‑care potential (Ref)

FDA accepted Nuvation Bio’s sNDA for IBTROZI with long-term data showing >4 years median response in both TKI-naïve and TKI-pretreated advanced ROS1+ NSCLC, with a target action date of January 4, 2027

Submission includes 10 months of additional follow-up from TRUST-I and TRUST-II studies (cutoff August 2025)

• TRUST-I (TKI-naïve): Median duration of response (mDOR) 49.7 months and median progression-free survival (mPFS) 49.6 months (>4 years)

  
  

• TRUST-II (TKI-pretreated): mDOR 19.4 months

Return to Top